Skip to Content

Relief Therapeutics Holding SA RLFTF

Morningstar Rating
$1.43 +0.03 (2.14%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RLFTF is trading at a 60% discount.
Price
$1.41
Fair Value
$5.79
Uncertainty
Extreme
1-Star Price
$72.85
5-Star Price
$1.93
Economic Moat
Wtxp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RLFTF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.40
Day Range
$1.351.43
52-Week Range
$1.209.00
Bid/Ask
$1.31 / $1.43
Market Cap
$17.47 Mil
Volume/Avg
3,790 / 3,163

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.36
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
69

Valuation

Metric
RLFTF
Price/Earnings (Normalized)
Price/Book Value
0.16
Price/Sales
2.36
Price/Cash Flow
Price/Earnings
RLFTF

Financial Strength

Metric
RLFTF
Quick Ratio
2.09
Current Ratio
2.30
Interest Coverage
Quick Ratio
RLFTF

Profitability

Metric
RLFTF
Return on Assets (Normalized)
−9.61%
Return on Equity (Normalized)
−12.99%
Return on Invested Capital (Normalized)
−12.85%
Return on Assets
RLFTF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQsttckgqhYbmsn$553.3 Bil
VRTX
Vertex Pharmaceuticals IncFvlqxfbkwXxfngm$101.6 Bil
REGN
Regeneron Pharmaceuticals IncMtcdbvzYjjtsz$98.9 Bil
MRNA
Moderna IncRpkdxhfKcpq$39.7 Bil
ARGX
argenx SE ADRBdtkkmzzlRhcgg$21.5 Bil
BNTX
BioNTech SE ADRMxwlrfcvDhn$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncZyhvsffkDmnqfxr$18.4 Bil
BMRN
Biomarin Pharmaceutical IncQpmzqjbxWpqrcqw$17.2 Bil
RPRX
Royalty Pharma PLC Class AVdzxfqtpGdhnx$12.3 Bil
INCY
Incyte CorpFmhhcmjwVgbxv$11.8 Bil

Sponsor Center